Mononucleosis and Epstein–Barr virus infection: treatment and medication

nonucleosis and Epstein–Barr virus infection: treatment and medication Review (2844) Total Article Views Authors: Valachis A, Kofteridis DP Published Date March 2012 Volume 2012:4 Pages 23 - 28 DOI: http://dx.doi.org/10.2147/VAAT.S17837 Received: 31 December 2011 Accepted: 13 February 2012 Published: 14 March 2012 Antonis Valachis2, Diamantis P Kofteridis1 1Departments of Internal Medicine-Infectious Disease Unit, University Hospital of Heraklion, Crete, Greece; 2Department of Oncology, M larsjukhuset, Eskilstuna, Sweden Abstract: Epstein–Barr virus is a member of the human herpes virus family. Primary infection is usually asymptomatic in childhood; in adolescents and young adults, however, it leads to infectious mononucleosis with symptoms including fever, fatigue, and sore throat that can persist for months. The disease is usually self-limited and resolves over a period of weeks or months but may occasionally be complicated by a wide variety of complications. Symptomatic treatment, the cornerstone of therapy, includes adequate hydration, analgesics, antipyretics, and limitations of contact sports and activities. The role of antiviral treatment and corticosteroids is debatable and not recommended in general, while the development of vaccination is under investigation. This review concentrates on the diagnosis, the potential complications, and the therapeutic strategies in patients with infectious mononucleosis.